Abstract
As resistance of influenza viruses to antiviral agents continues to evolve, new issues arise concerning appropriate therapy and novel therapeutic means that target influenza infections. Emergence of novel influenza mutations may lead to phenotypic as well as clinical resistance that may become a problem in serious influenza cases. Moreover, crucial public health issues emerge such as appropriate antiviral stockpiling for prepandemic and pandemic phases. The use of antiviral agents against seasonal, avian, and pandemic influenza should be an integral part of current pandemic preparedness planning and should be based on local and international surveillance data on antiviral resistance. As we tackle such resistance issues there appears to be an urgent need for developing strategies to conserve current antivirals against influenza, develop new agents or formulations that will exploit current pharmacokinetic knowledge, and study combination regimens.
Current Drug Targets
Title: Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
Volume: 10 Issue: 10
Author(s): Helen C. Maltezou and Sotirios Tsiodras
Affiliation:
Abstract: As resistance of influenza viruses to antiviral agents continues to evolve, new issues arise concerning appropriate therapy and novel therapeutic means that target influenza infections. Emergence of novel influenza mutations may lead to phenotypic as well as clinical resistance that may become a problem in serious influenza cases. Moreover, crucial public health issues emerge such as appropriate antiviral stockpiling for prepandemic and pandemic phases. The use of antiviral agents against seasonal, avian, and pandemic influenza should be an integral part of current pandemic preparedness planning and should be based on local and international surveillance data on antiviral resistance. As we tackle such resistance issues there appears to be an urgent need for developing strategies to conserve current antivirals against influenza, develop new agents or formulations that will exploit current pharmacokinetic knowledge, and study combination regimens.
Export Options
About this article
Cite this article as:
Maltezou C. Helen and Tsiodras Sotirios, Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577972
DOI https://dx.doi.org/10.2174/138945009789577972 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands
Current Medicinal Chemistry Activation and Regulation of Toll-like Receptor 9: CpGs and Beyond
Mini-Reviews in Medicinal Chemistry MCC950 Reduces Neuronal Apoptosis in Spinal Cord Injury in Mice
CNS & Neurological Disorders - Drug Targets Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Editorial: Uveitis: Pathology, Molecular Mechanisms and Therapy
Current Molecular Medicine Mesenchymal Stem Cells and Cell Therapy for Bone Repair
Current Molecular Pharmacology Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Synthetic Oligodeoxynucleotides Containing Deoxycytidyl-Deoxyguanosine Dinucleotides (CpG ODNs) and Modified Analogs as Novel Anticancer Therapeutics
Current Pharmaceutical Design Are 5-HT Levels Increased in Depression?
Current Psychiatry Reviews Developments in High-Yield System Expressed Vaccines and Immunotherapy
Recent Patents on Biotechnology Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
Current Topics in Medicinal Chemistry K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology The Database dbEST Correctly Predicts Gene Expression in Colon Cancer Patients
Current Pharmaceutical Biotechnology Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Editorial [Hot Topic: CD4+ Regulatory T Cells: Do They Treat Mucosal and Systemic Allergy and Inflammation? (Guest Editor: Noriko M. Tsuji)]
Inflammation & Allergy - Drug Targets (Discontinued) CYP Inhibition-Mediated Drug-Drug Interactions
Current Enzyme Inhibition Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Melatonin, Immune Function and Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery